Artivion rises as FDA clears minimally invasive aortic device

Artivion

07/04/2026 12:48

** Shares of medical device maker Artivion AORT.N rise 4.6% to $35 premarket

** Co says the FDA approved its NEXUS Aortic Arch System, which treats serious disease of the aorta, the body’s main artery, without open-chest surgery

** Co says the device can be used for aortic arch disease, including chronic tears in the artery wall, offering an alternative to high-risk surgery

** Says approval is backed by trial data showing high survival and low rates of stroke and repeat procedures

** Adds the clearance allows it to exercise an option to buy partner Endospan within 90 days

** Says it has secured a $150 mln loan to fund a potential Endospan acquisition

** As of last close, stock down ~27% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))